Christy J W Watson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7683428/publications.pdf

Version: 2024-02-01

		1040056	1058476		
19	241	9	14		
papers	citations	h-index	g-index		
19	19	19	263		
all docs	docs citations	times ranked	citing authors		

#	Article	IF	CITATIONS
1	Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metabolism and Disposition, 2021, 49, 1070-1080.	3.3	58
2	Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 182-193.	2.5	35
3	Comparison of tobacco-specific nitrosamine levelsÂin smokeless tobacco products: High levels in products from Bangladesh. PLoS ONE, 2020, 15, e0233111.	2.5	19
4	Regulation of UGT2A1 by miR-196a-5p and miR-196b-5p. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 234-243.	2.5	16
5	Nicotine- <i>N</i> ′-Oxidation by Flavin Monooxygenase Enzymes. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 311-320.	2.5	16
6	The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 21-29.	2.5	16
7	Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites. Drug Metabolism and Disposition, 2021, 49, 1081-1089.	3.3	14
8	Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors. Drug Metabolism and Disposition, 2019, 47, 535-544.	3.3	13
9	Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition. Journal of Medicinal Chemistry, 2018, 61, 7065-7086.	6.4	12
10	UDP-Glycosyltransferase 3A Metabolism of Polycyclic Aromatic Hydrocarbons: Potential Importance in Aerodigestive Tract Tissues. Drug Metabolism and Disposition, 2020, 48, 160-168.	3.3	9
11	Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver. Molecular Pharmacology, 2019, 96, 674-682.	2.3	6
12	Role of I- and d-Menthol in the Glucuronidation and Detoxification of the Major Lung Carcinogen, NNAL. Drug Metabolism and Disposition, 2019, 47, 1388-1396.	3.3	6
13	Expression of activating transcription factor 5 (ATF5) is mediated by microRNA-520b-3p under diverse cellular stress in cancer cells. PLoS ONE, 2020, 15, e0225044.	2.5	5
14	Characterization of cytosolic glutathione-S- transferases (GSTs) involved in the metabolism of the aromatase inhibitor, Exemestane. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2021-000635.	3.3	4
15	CYP2C19 plays a major role in the hepatic $\langle i \rangle N \langle i \rangle$ -oxidation of cotinine. Drug Metabolism and Disposition, 2022, , DMD-AR-2021-000624.	3.3	4
16	Prominent Stereoselectivity of NNAL Glucuronidation in Upper Aerodigestive Tract Tissues. Chemical Research in Toxicology, 2019, 32, 1689-1698.	3.3	3
17	Drug-Drug Interaction Between Orally Administered Hydrocodone-Acetaminophen and Inhalation of Cannabis Smoke: A Case Report. Hospital Pharmacy, 0, , 001857872110613.	1.0	3
18	Altered Metabolism of Polycyclic Aromatic Hydrocarbons by UDP-Glycosyltransferase 3A2 Missense Variants. Chemical Research in Toxicology, 2020, 33, 2854-2862.	3.3	2

 #	Article	IF	CITATIONS
19	Cytosolic glutathioneâ€Sâ€transferase A1 (GSTA1) plays a primary role in the metabolic clearance of the aromatase inhibitor, Exemestane. FASEB Journal, 2020, 34, 1-1.	0.5	0